| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
84,571,000 |
| Market
Cap: |
160.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7304 - $3.24 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s first two products were approved by the U.S. Food and Drug Administration, European Medicines Agency, and Swiss Agency for Therapeutic Products. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
59,611 |
74,217 |
| Total Buy Value |
$0 |
$0 |
$86,148 |
$171,738 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
0 |
0 |
1,913 |
51,775 |
| Total Sell Value |
$0 |
$0 |
$2,686 |
$239,770 |
| Total People Sold |
0 |
0 |
1 |
4 |
| Total Sell Transactions |
0 |
0 |
5 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcgovern Mark E |
Director |
– • – |
2016-07-05 |
4 |
B |
$10.00 |
$6,000 |
D/D |
600 |
600 |
2.39 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2016-05-04 |
4 |
B |
$14.85 |
$103,950 |
D/D |
7,000 |
41,614 |
2.81 |
- |
|
| Omenn Gilbert S |
Director |
– • – |
2016-03-01 |
4 |
B |
$15.28 |
$76,400 |
D/D |
5,000 |
10,000 |
2.39 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2016-01-27 |
4 |
B |
$15.88 |
$57,168 |
D/D |
3,600 |
34,614 |
2.81 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2016-01-15 |
4 |
B |
$14.08 |
$101,376 |
D/D |
7,200 |
31,014 |
2.81 |
- |
|
| Mcgowan Mary |
Chief Medical Officer |
• – – |
2015-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Braunstein Scott |
Director |
– • – |
2015-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
52 |
|
- |
|
| Goldstein Dov A Md |
Director |
– • – |
2015-04-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(199,991) |
1,637,125 |
|
- |
|
| Elms Steve |
10% Owner |
– – • |
2015-04-24 |
4 |
S |
$106.10 |
$7,169,373 |
I/I |
(67,469) |
1,837,125 |
|
- |
|
| Goldstein Dov A Md |
Director |
– • – |
2015-04-24 |
4 |
S |
$106.10 |
$7,169,373 |
I/I |
(67,469) |
1,837,125 |
|
- |
|
| Elms Steve |
10% Owner |
– – • |
2015-04-23 |
4 |
S |
$109.10 |
$16,365,000 |
I/I |
(150,000) |
1,904,594 |
|
- |
|
| Goldstein Dov A Md |
Director |
– • – |
2015-04-23 |
4 |
S |
$109.10 |
$16,365,000 |
I/I |
(150,000) |
1,904,594 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2015-03-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(350,000) |
2,216,935 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-03-19 |
4 |
S |
$110.01 |
$55,831,597 |
I/I |
(500,000) |
18,361 |
|
- |
|
| Alta Partners Viii, L.p. |
10% Owner |
– – • |
2015-02-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(842,222) |
1,709,967 |
|
- |
|
| Shah Nimesh |
10% Owner |
– – • |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
21,471 |
|
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2014-12-22 |
5 |
GD |
$0.00 |
$0 |
D/D |
500 |
23,814 |
|
- |
|
| Enright Patrick G |
Director |
– • • |
2014-11-18 |
4 |
S |
$31.56 |
$161,346 |
I/I |
(5,104) |
28,186 |
|
- |
|
| Tammenoms Bakker Juliet |
10% Owner |
– – • |
2014-11-18 |
4 |
S |
$31.56 |
$161,346 |
I/I |
(5,104) |
28,186 |
|
- |
|
| Enright Patrick G |
Director |
– • • |
2014-11-17 |
4 |
S |
$32.01 |
$15,804,823 |
I/I |
(482,026) |
28,286 |
|
- |
|
| Tammenoms Bakker Juliet |
10% Owner |
– – • |
2014-11-17 |
4 |
S |
$32.01 |
$15,804,823 |
I/I |
(482,026) |
28,286 |
|
- |
|
| Nohra Guy P |
10% Owner |
– – • |
2014-10-21 |
4 |
B |
$20.00 |
$10,000,000 |
I/I |
500,000 |
2,552,189 |
1.5 |
- |
|
| Janney Daniel |
Director |
– • • |
2014-10-21 |
4 |
B |
$20.00 |
$10,000,000 |
I/I |
500,000 |
2,552,189 |
2.25 |
- |
|
| Omenn Gilbert S |
Director |
– • – |
2014-10-21 |
4 |
B |
$20.00 |
$100,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-10-21 |
4 |
B |
$20.00 |
$10,000,000 |
D/D |
500,000 |
2,566,935 |
2.45 |
- |
|
250 Records found
|
|
Page 8 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (4.52%) 
